IP Library Patent Application 18385468
Patent Application
App. No. 18/385,468

EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/385,468
Abstract

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Claims (12)

1 . A pharmaceutical composition comprising a eutectic of mannitol and Cyclobenzaprine HCl.

2 . The pharmaceutical composition of claim 1 , comprising 60%-90% Cyclobenzaprine HCl and 40%-10% mannitol by weight.

3 . The pharmaceutical composition of claim 2 , comprising amounts of Cyclobenzaprine HCl and mannitol selected from: 60%±2% Cyclobenzaprine HCl and 40%±2% mannitol, 65%±2% Cyclobenzaprine HCl and 35%±2% mannitol, 70%±2% Cyclobenzaprine HCl and 30%±2% mannitol, 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol, 80%±2% Cyclobenzaprine HCl and 20%±2% mannitol, 85%±2% Cyclobenzaprine HCl and 15%±2% mannitol, and 90%±2% Cyclobenzaprine HCl and 10%±2% mannitol by weight.

4 . The pharmaceutical composition of claim 3 , comprising 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol by weight.

5 . The pharmaceutical composition of claim 1 , wherein the Cyclobenzaprine HCl:mannitol molar ratio is 1.76±0.1.

6 . The pharmaceutical composition of claim 1 , wherein the Cyclobenzaprine HCl is micronized Cyclobenzaprine HCl.

7 . The pharmaceutical composition of claim 1 , further comprising a basifying agent.

8 . The pharmaceutical composition of claim 7 , wherein the basifying agent is K 2 HPO 4 .

9 . The pharmaceutical composition of claim 7 , wherein the basifying agent is Na 2 HPO 4 .

10 . The pharmaceutical composition of claim 7 , wherein the basifying agent is trisodium citrate, anhydrous.

11 .- 53 . (canceled)

54 . The pharmaceutical composition of claim 7 , wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate (KH 2 PO 4 ), dipotassium hydrogen phosphate (K 2 HPO 4 ), tripotassium phosphate (K 3 PO 4 ), sodium dihydrogen phosphate (NaH 2 PO 4 ), disodium hydrogen phosphate (Na 2 HPO 4 ), trisodium phosphate (Na 3 PO 4 ), trisodium citrate anhydrous, a bicarbonate salt, a carbonate salt, borate, hydroxide, silicate, nitrate, dissolved ammonia, bicarbonate, and sulfide.

Assignments (4)
NOVATION AGREEMENT Recorded Jul 8, 2024
From: TONIX PHARMA HOLDINGS LIMITED
To: TONIX PHARMA LIMITED
Reel/Frame 068217/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: NEBULONI, MARINO; COLOMBO, PATRIZIA
To: REDOX SRL
Reel/Frame 065402/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: REDOX SRL
To: TONIX PHARMACEUTICALS, INC.
Reel/Frame 065402/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: TONIX PHARMACEUTICALS, INC.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 065412/0773 →